Smithfield Trust’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-490
Closed 1123
2020
Q4
$0 Hold
490
﹤0.01% 1123
2020
Q3
$1K Buy
490
+150
+44% +$428 ﹤0.01% 1081
2020
Q2
$1K Buy
+340
New +$1.23K ﹤0.01% 1033
2020
Q1
Sell
-132
Closed 1035
2019
Q4
$0 Buy
+132
New +$343 ﹤0.01% 1015

Other funds holding BMY.RT

Smithfield Trust's BMY.RT Position: Q1 2021 in Review

Smithfield Trust sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 490 shares.

Smithfield Trust first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $1K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Smithfield Trust reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Smithfield Trust sold 490 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Smithfield Trust first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Smithfield Trust's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Smithfield Trust's 13F filing for Q1 2021, filed 14 May 2021.